

Trial ID: AML-UK-001 started on 2023-01-31 in London. The trial is expected to last 12 months and is in Phase 1 stage. The treatment being tested is CAR-T Therapy, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-002 started on 2023-02-28 in Manchester. The trial is expected to last 24 months and is in Phase 2 stage. The treatment being tested is Venetoclax, and the focus of the trial is to assess its toxicity. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-003 started on 2023-03-31 in Edinburgh. The trial is expected to last 18 months and is in Phase 3 stage. The treatment being tested is Cytarabine, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-004 started on 2023-04-30 in Birmingham. The trial is expected to last 36 months and is in Phase 3 stage. The treatment being tested is Stem Cell Transplant, and the focus of the trial is to assess its toxicity. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-005 started on 2023-05-31 in Oxford. The trial is expected to last 12 months and is in Phase 2 stage. The treatment being tested is Azacitidine, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-006 started on 2023-06-30 in Cambridge. The trial is expected to last 30 months and is in Phase 1 stage. The treatment being tested is Decitabine, and the focus of the trial is to

assess its toxicity. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-007 started on 2023-07-31 in Bristol. The trial is expected to last 18 months and is in Phase 1 stage. The treatment being tested is Ivosidenib, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-008 started on 2023-08-31 in Leeds. The trial is expected to last 24 months and is in Phase 2 stage. The treatment being tested is Chemotherapy, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-009 started on 2023-09-30 in Liverpool. The trial is expected to last 15 months and is in Phase 3 stage. The treatment being tested is Venetoclax, and the focus of the trial is to assess its toxicity. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-010 started on 2023-10-31 in Glasgow. The trial is expected to last 22 months and is in Phase 2 stage. The treatment being tested is Enasidenib, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-011 started on 2023-11-30 in Cardiff. The trial is expected to last 28 months and is in Phase 1 stage. The treatment being tested is FLT3 Inhibitors, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-012 started on 2023-12-31 in Sheffield. The trial is expected to last 10 months and is in Phase 1 stage. The treatment being tested is Gilteritinib, and the focus of the trial is to assess its toxicity. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-013 started on 2024-01-31 in Newcastle. The trial is expected to last 14 months and is in Phase 3 stage. The treatment being tested is Targeted Therapy, and the focus of the trial is to assess its toxicity. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-014 started on 2024-02-29 in Leicester. The trial is expected to last 26 months and is in Phase 2 stage. The treatment being tested is Venetoclax + Azacitidine, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-015 started on 2024-03-31 in Nottingham. The trial is expected to last 18 months and is in Phase 3 stage. The treatment being tested is Immunotherapy, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-016 started on 2024-04-30 in Southampton. The trial is expected to last 20 months and is in Phase 2 stage. The treatment being tested is Chemotherapy + Ivosidenib, and the focus of the trial is to assess its toxicity. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-017 started on 2024-05-31 in Aberdeen. The trial is expected to last 16 months

and is in Phase 1 stage. The treatment being tested is Stem Cell Transplant, and the focus of the trial is to assess its toxicity. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-018 started on 2024-06-30 in Reading. The trial is expected to last 34 months and is in Phase 3 stage. The treatment being tested is Venetoclax, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-019 started on 2024-07-31 in Brighton. The trial is expected to last 12 months and is in Phase 2 stage. The treatment being tested is FLT3 Inhibitors, and the focus of the trial is to assess its toxicity. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-020 started on 2024-08-31 in Coventry. The trial is expected to last 30 months and is in Phase 1 stage. The treatment being tested is Decitabine, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-021 started on 2024-09-30 in York. The trial is expected to last 18 months and is in Phase 1 stage. The treatment being tested is CAR-T Therapy, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.

Trial ID: AML-UK-022 started on 2024-10-31 in Dundee. The trial is expected to last 20 months and is in Phase 2 stage. The treatment being tested is Gilteritinib, and the focus of the trial is to assess its toxicity. This study aims to provide valuable insights for improving treatment outcomes in patients

with AML.

Trial ID: AML-UK-023 started on 2024-11-30 in Exeter. The trial is expected to last 25 months and is in Phase 3 stage. The treatment being tested is Enasidenib, and the focus of the trial is to assess its efficacy. This study aims to provide valuable insights for improving treatment outcomes in patients with AML.